Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B



Status:Completed
Conditions:Hepatitis
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:11/8/2014
Start Date:August 2011
End Date:March 2012
Contact:Humberto C Gonzalez, MD
Email:hgonzal1@hfhs.org
Phone:313-916-2424

Use our guide to learn which trials are right for you!

Post Transplant Course of Hepatitis C Patients After Living Donor Liver Transplant in Association With Interleukin 28 B

Hepatitis C is the leading cause of liver transplants in the USA. Given that there is a
national organ shortage, living donor liver transplantation has became a viable option for
patients with end stage liver disease who are not severely ill. Recently particular
polymorphisms of IL-28B gene were reported to correlate with histological recurrence and
antiviral treatment response after orthotopic liver transplantation for hepatitis C. Similar
results have not been described yet in living donor liver transplant patients.

There is data suggesting slightly inferior outcomes in living donor liver transplants when
done for hepatitis C. The investigators postulate that such inferior outcomes may be related
to IL28 polymorphism concordance (i.e., unfavorable recipient polymorphism patients receive
similarly unfavorable polymorphism livers from their relatives).


Inclusion Criteria:

- Patients who received a living donor liver transplant for chronic hepatitis C who are
18 year or older

- Patients who donated part of their liver to patients suffering from chronic hepatitis
C. Donors must be 18 years or older

Exclusion Criteria:

- Patients who are not willing to sign the consent

- Inability to obtain liver specimen (recipients)

- Inability to obtain blood sample (donors)
We found this trial at
1
site
2799 W Grand Blvd
Detroit, Michigan 48202
(313) 916-2600
Henry Ford Hospital Founded in 1915 by auto pioneer Henry Ford and now one of...
?
mi
from
Detroit, MI
Click here to add this to my saved trials